Gilead Sciences Inc. said it began clinical tests at Johns Hopkins University to determine the safety of its compound GS 840 in patients infected with HIV.
The drug is an oral version of an injectible Gilead GS 393, which is undergoing studies for use against the virus that causes AIDS.
